{"id":"NCT01294423","sponsor":"AstraZeneca","briefTitle":"Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus","officialTitle":"A 24-week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2011-02-11","resultsPosted":"2013-08-23","lastUpdate":"2014-07-24"},"enrollment":261,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes","High Blood Sugar"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 24-week randomised, multi-centre phase III study to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with Type 2 diabetes mellitus who have inadequate glycemic control with diet and exercise.","primaryOutcome":{"measure":"Adjusted Mean Change in HbA1c Levels","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Dapagliflozin 5 mg","deltaMin":-0.41,"sd":null},{"arm":"Dapagliflozin 10 mg","deltaMin":-0.45,"sd":null},{"arm":"Placebo","deltaMin":-0.06,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":26,"countries":["Japan"]},"refs":{"pmids":["24909293","38770818"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=298&filename=CSR-D1692C00006.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=298&filename=CSR-D1692C00006.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=298&filename=D1692C00006_Clinical_Study_Protocol_and_Amendment_8536419317510300265.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":86},"commonTop":["NASOPHARYNGITIS","HYPERTENSION"]}}